Hoffmann-La Roche, Inc.

DELRAY BEACH, Fla., June 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Cardiac Marker Testing Market is projected to grow from about USD 5.54 billion in 2026 to USD 9.06 billion by 2031, at a CAGR of 10.3%. Browse 457 market data Tables and 55 Figures spread through 372 Pages and in-depth TOC on 'Cardiac Marker Testing Market - Global Forecast to 2031' Cardiac Marker Testing Market Size & Forecast: Market Size Available for Years: 2025–2031 2026 Market Size: USD 5.54 billion 2031 Projected Market Size: USD 9.06 billion CAGR (2026–2031): 10.3% Cardiac Marker Testing Market Trends & Insights: The reagents & kits segment is expected to register the highest growth rate with 11%. Troponin I & T leads the market with a share of 40.3% in 2025. Lab tests accounted for the largest market share of 74.7% in 2025. Multiplex assay to grow at the highest rate of 11.6%. Download PDF Brochure @ The main drivers of the market are the growing use of point-of-care testing solutions and the rising demand for rapid test results in emergency situations. The demand for cardiac marker testing is also fueled by the increasing geriatric population and the prevalence of lifestyle diseases such as obesity and diabetes. The increasing focus on decentralized healthcare systems is also a major driver of the cardiac marker testing market. The growing focus on developing new technologies for multiplex biomarker testing is also a key driver of the cardiac marker testing market. Moreover, market growth depends significantly on technological advancements that provide substantial benefits to the industry. The creation of highly sensitive cardiac biomarker assays, the use of laboratory automation, and the integration of digital health and data management systems have improved diagnostic efficiency and decision-making. Healthcare providers and diagnostic companies can utilize more reliable and efficient testing solutions due to industry innovations, including advanced immunoassay technologies, multiplex testing, and assay specificity for early detection. Additionally, testing solutions have been validated to help manage complex clinical conditions and accurately assess patients from diverse populations. In the cardiac marker testing market, the reagents & kits segment accounted for the larger share within the product segment in 2026. This market is segmented into reagents/kits and instruments. Factors that drive the growth of the reagents/kits segment include the growing demand for advanced diagnostic solutions, the growing incidence of cardiovascular diseases, and the need to obtain quick and accurate results. Moreover, the expansion of diagnostic labs and infrastructure, combined with the constant improvement in the quality of automated testing equipment, is also fueling the demand for cardiac marker testing instruments. Request Sample Pages@ In the cardiac marker testing market, the point-of-care testing segment is projected to register the highest growth during the forecast period. The end users of the cardiac marker testing market include diagnostic labs, academic institutes, and point-of-care testing. The point-of-care testing segment is witnessing a strong growth trend, and this can be attributed to a number of factors, such as the rising need to achieve quick results in emergency and critical care settings. The increasing incidence of CVD and the need to achieve quick decision-making in patient care settings have led to a number of healthcare providers adopting point-of-care testing solutions for cardiac testing. The increased emphasis on decentralized patient care and the need to improve patient outcomes through quick diagnosis also contribute to the growth of point-of-care testing solutions for cardiac markers. North America dominated the cardiac marker testing market in 2026. The cardiac marker testing market segments are classified into five regions: Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa. North America accounted for the highest market share in the cardiac marker testing market in 2025. The market in this region is growing due to its healthcare infrastructure, high incidence rate of cardiovascular diseases, and the increased number of diagnostic tests performed in this region. High demand for cardiac marker testing in this region is due to the presence of high-end diagnostic centers and hospitals, along with stringent regulatory conditions for diagnostic accuracy, quality, and early detection of diseases. Inquire Before Buying@ Top Companies in Cardiac Marker Testing Market: The Top Companies in Cardiac Marker Testing Market include Siemens (Germany), Roche Hoffmann (Switzerland), Danaher (US), Laboratories Abbott (US), Thermo Scientific (US), BD (US), Bio-Rad (US), Revvity (US), DiaSorin SPA (Italy), and Quidel Corporation (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Related Reports: Lateral Flow Assays Market - Global Forecast to 2030 In Vitro Diagnostics Market - Global Forecast to 2030 Point of Care Diagnostics Market - Global Forecast to 2029 Biomarkers Market - Global Forecast to 2030 Cardiac Monitoring and Cardiac Rhythm Management Devices Market - Global Forecast to 2031 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: Logo: SOURCE MarketsandMarkets 21% more press release views with Request a Demo

DELRAY BEACH, Fla., May 18, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Cancer Biomarkers Market is projected to grow from about USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6%. Browse 493 market data Tables and 50 Figures spread through 550 Pages and in-depth TOC on "Cancer Biomarkers Market - Global Forecast to 2032" Cancer Biomarkers Market Size & Forecast: Market Size Available for Years: 2025–2032 2026 Market Size: USD 28.25 billion 2032 Projected Market Size: USD 54.48 billion CAGR (2026–2032): 11.6% Cancer Biomarkers Market Trends & Insights: The diagnostics segment leads the market with the share of 51.0% in 2025. The consumables segment is expected to register the highest growth rate with 12.0%. North America led the market share in 2025. Download PDF Brochure @ The growth in the market will primarily be attributed to the use of biomarkers in oncological treatment approaches, along with rising cancer rates worldwide. Other factors that have led to the substantial growth of the cancer biomarkers market include the use of precision medicines and innovative methods for identifying biomarkers through genomics, proteomics, and multi-omics. Despite all the above-mentioned positive factors, there are certain limitations within the market. High costs required to perform complex diagnostic procedures, such as next-generation sequencing and multi-omics, pose an obstacle to their more frequent use, especially in developing countries. Moreover, issues with insurance coverage are another obstacle that prevents many patients from receiving biomarker-based diagnostics. Issues such as variability in sampling and processing also need to be considered when considering these tests. In the cancer biomarkers market, the omics technology segment accounted for the largest share within the profiling technology segment in 2026. The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. As of 2025, the cancer biomarkers market was dominated by the omics technology segment, mainly due to the high-throughput nature of these technologies in cancer biomarker discovery and diagnosis. Request Sample Pages@ In the cancer biomarkers market, the breast cancer segment accounted for the largest share within the cancer type segment in 2026. The market for cancer biomarkers is divided into categories by cancer type: non-Hodgkin lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In 2025, the market for cancer biomarkers was dominated by the breast cancer segment. The huge share of this segment is due to the growing rate of breast cancer cases worldwide, followed by awareness for diagnosis, prevention, and treatment. North America dominated the cancer biomarkers market in 2026. The cancer biomarkers market is segmented into six regions: Asia Pacific, Latin America, North America, Europe, the Middle East & Africa, and GCC Countries. North America held the largest market share in the cancer biomarkers market in 2026. The market in this region is growing due to its healthcare infrastructure, high cancer incidence, and increased number of diagnostic tests performed. High demand for cancer biomarkers in this region is driven by the presence of high-end diagnostic centers and hospitals, along with stringent regulatory requirements for diagnostic accuracy, quality, and early disease detection. Inquire Before Buying@ Top Companies in Cancer Biomarkers Market: The Top Companies in Cancer Biomarkers Market include Thermo Fisher (US), Roche Hoffmann (Switzerland), Illumina (US), Quest Diagnostics (US), and Agilent Technologies (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Related Reports: Patient Derived Xenografts/PDX Models Market - Global Forecast to 2030 Biomarkers Market - Global Forecast to 2030 Genomics Market - Global Forecast to 2030 Precision Diagnostics & Medicine Market - Global Forecast to 2029 Proteomics Market - Global Forecast to 2031 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: Logo: SOURCE MarketsandMarkets 21% more press release views with Request a Demo

Results point to Enspryng® (Satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammation. WASHINGTON, DC, UNITED STATES, April 21, 2026 / EINPresswire.com / -- The MOG Project is thrilled to share its excitement on the positive results Hoffmann La-Roche and Genentech announced today regarding a 44-month randomized double-blind placebo-controlled study on MOGAD. The findings were presented at the scientific meeting of the American Academy of Neurology (AAN) being held in Chicago, IL. The goal of the METEROID trial was to confirm the efficacy and safety of Satralizumab in preventing MOGAD relapses, especially for individuals with recurrent episodes of this rare disease. Enspryng ® reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with MOGAD. There were no safety signals and the safety profile was consistent with over a decade of use in another neuroimmune disease, NMOSD. Importantly, a key secondary endpoint showed that Enspryng ® has the potential to reduce central nervous system inflammation and the use of rescue therapies such as steroids, plasma exchange, or intravenous immunoglobulins. In commenting on the success of the Enspryng ® trial, Julia Lefelar, Co-Founding Executive Director and Amy Ednie, Co-Founding President of The MOG Project, the leading global nonprofit health organization wholly dedicated to MOGAD, issued the following statement: “For children and adults with MOGAD and their loved ones, this is an historic day! With no approved MOGAD specific treatments, the announcement by Hoffmann La Roche and Genentech indicates that it is possible to develop safe and effective therapies for MOGAD. The MOGAD global community is greatly encouraged by the positive and significant results of this pioneering clinical trial which has demonstrated that the PHASE III trial met its primary endpoint, i.e., to prevent the onset of MOGAD relapses. We are also extremely encouraged that Enspryng ® may reduce inflammation to a point where use of rescue therapies, such as steroids, plasma exchange, and intravenous immunoglobulins, may also be reduced. These results provide hope that this complex neuroimmune disease can be brought under control and that, eventually, a cure can be found for the thousands of children and adults living with MOGAD worldwide.” Enspryng ® blocks the Interlukin-6 (IL-6) receptor which prevents it from causing inflammation and aims to prevent future attacks or relapses. There are no approved medications for MOGAD, so this announcement today has been long awaited by a global audience of patients with the disease. This same therapy was previously approved by the U.S. Food and Drug Administration (FDA) and other international authorities for Neuromyelitis Optic Spectrum (NMOSD), a different autoimmune disease of the central nervous system. Interlukin-6 is involved in NMOSD. MOGAD, or Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, is a rare autoimmune disease of the central nervous system. In MOGAD, the immune system attacks myelin, the protective sheath around nerves in the brain, spinal cord, and eyes, causing inflammation and damage. This may lead to vision loss, muscle weakness, confusion, and paralysis, often presenting as a single attack or multiple relapses, which may cause disability. The disease mimics Multiple Sclerosis (MS) but has distinct diagnostic differences, such as MOG-specific antibodies and specific MRI patterns. Julia Lefelar The MOG Project +1 301-928-5491 Julia.Lefelar@themogproject.org Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.